The success of an AI-assisted scientific review pilot spurs the US Food and Drug Administration to take on a complete artificial intelligence overhaul – all within the next 52 days.
US Food and Drug Administration (FDA) Commissioner Martin A. Makary announced the “historic” AI-overhaul on Thursday, directing all FDA centers to begin deployment immediately, with the goal of full integration by the end of June.
The plan will centralize the operations of all fourteen FDA centers on a common, secure generative AI system integrated with FDA’s internal data platforms, according to Thursday’s announcement.
Incorporating AI will help the agency to “expand use cases, improve functionality, and adapt to the evolving needs of each center,” it said.
To reflect the urgency of this effort, Dr. Makary has directed all FDA centers to begin deployment immediately, with the goal of full integration by the end of June. Work will continue to expand use cases, improve functionality and adapt to the evolving needs of each center after…
undefined U.S. FDA (@US_FDA) May 8, 2025
The decision for an aggressive agency-wide rollout timeline was triggered by the recent conclusion of an AI-pilot program, in which FDA scientists and subject-matter experts adopted the use of AI tools to help with the scientific review process.
America’s health watchdog said the tools allowed scientists to spend less time on tedious, repetitive tasks that often slow down the drug approval review process, which presently takes between six to 10 months from the day the FDA first receives an application.
Deputy Director of the FDA’s Offices of Drug Evaluation Sciences and New Drugs, Jinzhong (Jin) Liu, called the technology a “game changer” for boosting productivity, allowing him to complete “scientific review tasks in minutes that used to take three days.”
The Commissioner said he was “blown away” by the success of the generative AI scientific review pilot program.
“We need to value our scientists’ time and reduce the amount of non-productive busywork that has historically consumed much of the review process. The agency-wide deployment of these capabilities holds tremendous promise in accelerating the review time for new therapies,” Dr. Makary said.
I was blown away by the success of our first AI-assisted scientific review pilot. We need to value our scientists’ time and reduce the amount of non-productive busywork that has historically consumed much of the review process. The agency-wide deployment of these capabilities… https://t.co/5OemExtCwY
undefined Dr. Martin Makary (@DrMakaryFDA) May 8, 2025
“There have been years of talk about AI capabilities in frameworks, conferences and panels but we cannot afford to keep talking. It is time to take action. The opportunity to reduce tasks that once took days to just minutes is too important to delay,” said Dr. Makary.
The FDA said future enhancements will focus on improving usability, expanding document integration, and tailoring outputs to center-specific needs, while maintaining strict information security and compliance with FDA policy.
The agency-wide rollout is being coordinated by the FDA’s newly appointed Chief AI OfficerJeremy Walsh, and Sridhar Mantha, Director of Strategic Programs for the FDA’s Center for Drug Evaluation and Research (CDER).
The agency will continue to assess performance, gather user feedback and refine features to support the evolving needs of FDA staff and advance its public health mission it said, adding that more details and updates will be shared wit the public in June.
Your email address will not be published. Required fields are markedmarked